Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46


Identification of targetable recurrent MAP3K8 rearrangements in melanomas lacking known driver mutations.

Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sanchez V, Shyr Y, Sanders ME, Pietenpol JA.

Mol Cancer Res. 2019 Jun 11. pii: molcanres.0257.2019. doi: 10.1158/1541-7786.MCR-19-0257. [Epub ahead of print]


Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility.

Whalen DS, Widatalla SE, Korolkova OY, Nangami GS, Beasley HK, Williams SD, Virgous C, Lehmann BD, Ochieng J, Sakwe AM.

Oncotarget. 2019 Jan 4;10(2):133-151. doi: 10.18632/oncotarget.26512. eCollection 2019 Jan 4.


First international TNBC conference meeting report.

Rida P, Ogden A, Ellis IO, Varga Z, Wolff AC, Traina TA, Hatzis C, Palmer JR, Ambrosone CB, Lehmann BD, Nanda R, Montgomery Rice V, Brawley OW, Torres MA, Rakha E, Aneja R.

Breast Cancer Res Treat. 2018 Jun;169(3):407-412. doi: 10.1007/s10549-018-4692-3. Epub 2018 Feb 8.


The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer.

Guo Y, Yu H, Wang J, Sheng Q, Zhao S, Zhao YY, Lehmann BD.

Genes (Basel). 2018 Jan 10;9(1). pii: E29. doi: 10.3390/genes9010029.


Estimating relative mitochondrial DNA copy number using high throughput sequencing data.

Zhang P, Lehmann BD, Samuels DC, Zhao S, Zhao YY, Shyr Y, Guo Y.

Genomics. 2017 Oct;109(5-6):457-462. doi: 10.1016/j.ygeno.2017.07.002. Epub 2017 Jul 19.


Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue.

Jovanović B, Sheng Q, Seitz RS, Lawrence KD, Morris SW, Thomas LR, Hout DR, Schweitzer BL, Guo Y, Pietenpol JA, Lehmann BD.

BMC Cancer. 2017 Apr 4;17(1):241. doi: 10.1186/s12885-017-3237-1.


A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.

Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA.

Clin Cancer Res. 2017 Aug 1;23(15):4035-4045. doi: 10.1158/1078-0432.CCR-16-3055. Epub 2017 Mar 7.


The Utilization of Formalin Fixed-Paraffin-Embedded Specimens in High Throughput Genomic Studies.

Zhang P, Lehmann BD, Shyr Y, Guo Y.

Int J Genomics. 2017;2017:1926304. doi: 10.1155/2017/1926304. Epub 2017 Jan 26. Review.


Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.

Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA.

PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016.


Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies.

Shaver TM, Lehmann BD, Beeler JS, Li CI, Li Z, Jin H, Stricker TP, Shyr Y, Pietenpol JA.

Cancer Res. 2016 Aug 15;76(16):4850-60. doi: 10.1158/0008-5472.CAN-16-0058. Epub 2016 May 26.


Erratum to: Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.

Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS.

BMC Cancer. 2016 Apr 18;16:275. doi: 10.1186/s12885-016-2307-0. No abstract available.


Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.

Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS.

BMC Cancer. 2016 Feb 23;16:143. doi: 10.1186/s12885-016-2198-0. Erratum in: BMC Cancer. 2016;16(1):275.


Clinical implications of molecular heterogeneity in triple negative breast cancer.

Lehmann BD, Pietenpol JA.

Breast. 2015 Nov;24 Suppl 2:S36-40. doi: 10.1016/j.breast.2015.07.009. Epub 2015 Aug 5. Review.


Triple-negative breast cancer: molecular subtypes and new targets for therapy.

Lehmann BD, Pietenpol JA, Tan AR.

Am Soc Clin Oncol Educ Book. 2015:e31-9. doi: 10.14694/EdBook_AM.2015.35.e31.


Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer.

Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D.

Oncotarget. 2015 Aug 28;6(25):21353-68.


A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.

Mohni KN, Thompson PS, Luzwick JW, Glick GG, Pendleton CS, Lehmann BD, Pietenpol JA, Cortez D.

PLoS One. 2015 May 12;10(5):e0125482. doi: 10.1371/journal.pone.0125482. eCollection 2015.


Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.

Lehmann BD, Ding Y, Viox DJ, Jiang M, Zheng Y, Liao W, Chen X, Xiang W, Yi Y.

BMC Cancer. 2015 Mar 26;15:179. doi: 10.1186/s12885-015-1102-7.


Detection of internal exon deletion with exon Del.

Guo Y, Zhao S, Lehmann BD, Sheng Q, Shaver TM, Stricker TP, Pietenpol JA, Shyr Y.

BMC Bioinformatics. 2014 Oct 16;15:332. doi: 10.1186/1471-2105-15-332.


PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.

Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA.

Breast Cancer Res. 2014 Aug 8;16(4):406. doi: 10.1186/s13058-014-0406-x.


Subtyping of triple-negative breast cancer: implications for therapy.

Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA.

Cancer. 2015 Jan 1;121(1):8-16. doi: 10.1002/cncr.28914. Epub 2014 Jul 16. Review.


Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.

Jovanović B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL.

Breast Cancer Res. 2014 Jul 1;16(4):R69. doi: 10.1186/bcr3684.


Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer.

Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK.

Cancer Res. 2014 Jun 1;74(11):3180-94. doi: 10.1158/0008-5472.CAN-13-3415. Epub 2014 Mar 24.


New strategies for triple-negative breast cancer--deciphering the heterogeneity.

Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA.

Clin Cancer Res. 2014 Feb 15;20(4):782-90. doi: 10.1158/1078-0432.CCR-13-0583. Review.


Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL.

Cancer Discov. 2014 Feb;4(2):232-45. doi: 10.1158/2159-8290.CD-13-0286. Epub 2013 Dec 19.


BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.

Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W.

Clin Cancer Res. 2013 Dec 15;19(24):6696-702. doi: 10.1158/1078-0432.CCR-13-1746.


Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.

Lehmann BD, Pietenpol JA.

J Pathol. 2014 Jan;232(2):142-50. doi: 10.1002/path.4280. Review.


Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.

Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT.

Clin Cancer Res. 2013 Oct 1;19(19):5533-40. doi: 10.1158/1078-0432.CCR-13-0799. Epub 2013 Aug 15.


SPARCL1 suppresses metastasis in prostate cancer.

Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann BD, Strand DW, Jovanovic B, DeGraff DJ, Zheng Y, Yousif DA, Simmons CQ, Case TC, Yi J, Cates JM, Virostko J, He X, Jin X, Hayward SW, Matusik RJ, George AL Jr, Yi Y.

Mol Oncol. 2013 Dec;7(6):1019-30. doi: 10.1016/j.molonc.2013.07.008. Epub 2013 Jul 20.


Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.

Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, Pietenpol JA, Shao ZM, Symmans WF, Chang JC.

Clin Cancer Res. 2013 May 15;19(10):2723-33. doi: 10.1158/1078-0432.CCR-12-2986. Epub 2013 Apr 2.


A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer.

Qiu Q, Lu P, Xiang Y, Shyr Y, Chen X, Lehmann BD, Viox DJ, George AL Jr, Yi Y.

PLoS One. 2013;8(1):e54979. doi: 10.1371/journal.pone.0054979. Epub 2013 Jan 29.


Patient-derived breast tumor xenografts facilitating personalized cancer therapy.

Landis MD, Lehmann BD, Pietenpol JA, Chang JC.

Breast Cancer Res. 2013 Jan 22;15(1):201. doi: 10.1186/bcr3355. Review.


p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.

Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA.

Cell Cycle. 2012 Dec 15;11(24):4579-88. doi: 10.4161/cc.22852. Epub 2012 Nov 27.


Targeting mutant p53 in human tumors.

Lehmann BD, Pietenpol JA.

J Clin Oncol. 2012 Oct 10;30(29):3648-50. doi: 10.1200/JCO.2012.44.0412. Epub 2012 Sep 10. Review. No abstract available.


TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.

Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA.

Cancer Inform. 2012;11:147-56. doi: 10.4137/CIN.S9983. Epub 2012 Jul 24.


Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.

Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS, McCubrey JA.

Oncotarget. 2011 Aug;2(8):610-26.


Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA.

J Clin Invest. 2011 Jul;121(7):2750-67. doi: 10.1172/JCI45014.


RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA.

Breast Cancer Res. 2010;12(3):R41. doi: 10.1186/bcr2595. Epub 2010 Jun 24.


Attenuation of myocardial injury in mice with functional deletion of the circadian rhythm gene mPer2.

Virag JA, Dries JL, Easton PR, Friesland AM, DeAntonio JH, Chintalgattu V, Cozzi E, Lehmann BD, Ding JM, Lust RM.

Am J Physiol Heart Circ Physiol. 2010 Mar;298(3):H1088-95. doi: 10.1152/ajpheart.01280.2008. Epub 2010 Jan 8.


Senescence-associated exosome release from human prostate cancer cells.

Lehmann BD, Paine MS, Brooks AM, McCubrey JA, Renegar RH, Wang R, Terrian DM.

Cancer Res. 2008 Oct 1;68(19):7864-71. doi: 10.1158/0008-5472.CAN-07-6538.


Targeting prostate cancer based on signal transduction and cell cycle pathways.

Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, Martelli AM, Steelman LS, McCubrey JA.

Cell Cycle. 2008 Jun 15;7(12):1745-62. Epub 2008 Jun 16. Review.


Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

McCubrey JA, Sokolosky ML, Lehmann BD, Taylor JR, Navolanic PM, Chappell WH, Abrams SL, Stadelman KM, Wong EW, Misaghian N, Horn S, Bäsecke J, Libra M, Stivala F, Ligresti G, Tafuri A, Milella M, Zarzycki M, Dzugaj A, Chiarini F, Evangelisti C, Martelli AM, Terrian DM, Franklin RA, Steelman LS.

Adv Enzyme Regul. 2008;48:113-35. doi: 10.1016/j.advenzreg.2008.02.006. Epub 2008 Feb 21. No abstract available.


Distinct roles for p107 and p130 in Rb-independent cellular senescence.

Lehmann BD, Brooks AM, Paine MS, Chappell WH, McCubrey JA, Terrian DM.

Cell Cycle. 2008 May 1;7(9):1262-8. Epub 2008 Mar 7.


Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman KM, Terrian DM, Leslie NR, Martelli AM, Stivala F, Libra M, Franklin RA, McCubrey JA.

Oncogene. 2008 Jul 3;27(29):4086-95. doi: 10.1038/onc.2008.49. Epub 2008 Mar 10.


Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.

Lehmann BD, McCubrey JA, Terrian DM.

Cancer Biol Ther. 2007 Aug;6(8):1165-70. Epub 2007 Aug 5. Review.


Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH, Wong EW, Lehmann BD, Terrian DM, Basecke J, Stivala F, Libra M, Evangelisti C, Martelli AM.

Adv Enzyme Regul. 2007;47:64-103. Epub 2007 Mar 26. No abstract available.


A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells.

Lehmann BD, McCubrey JA, Jefferson HS, Paine MS, Chappell WH, Terrian DM.

Cell Cycle. 2007 Mar 1;6(5):595-605. Epub 2007 Mar 18.


Supplemental Content

Loading ...
Support Center